SCHEMBL6243453

SCHEMBL6243453

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCC3CCSC3=O)c3ccccc23)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.67
MAPK12 P53778 10/20 0.67
HCK P08631 9/20 0.67
TNF P01375 5/20 0.67
CIT O14578 1/20 0.66
MUSK O15146 1/20 0.66
MAPK13 O15264 1/20 0.66
MAP3K7 O43318 1/20 0.66
RIPK2 O43353 1/20 0.66
STK10 O94804 1/20 0.66
MAP4K4 O95819 1/20 0.66
CHEK2 O96017 1/20 0.66
ABL1 P00519 1/20 0.66
EGFR P00533 1/20 0.66
RAF1 P04049 1/20 0.66
NTRK1 P04629 1/20 0.66
HSPB1 P04792 1/20 0.66
PRKCB P05771 1/20 0.66
LCK P06239 1/20 0.66
FYN P06241 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365566 0.85 MAPK14 (0.78) MAPK14MAPK12HCKTNFCIT
SCHEMBL29593878 0.85 MAPK14 (0.70) MAPK14MAPK12HCKTNFCIT
SCHEMBL295776 0.85 MAPK14 (0.70) MAPK14MAPK12HCKTNFCIT
SCHEMBL29594339 0.85 MAPK14 (0.79) MAPK14MAPK12HCKTNFCIT
SCHEMBL294689 0.85 MAPK14 (0.79) MAPK14MAPK12HCKTNFCIT
SCHEMBL6298579 0.84 MAPK14 (0.79) MAPK14MAPK12HCKTNFCIT
SCHEMBL29593481 0.84 MAPK14 (0.71) MAPK14MAPK12HCKTNFCIT
SCHEMBL294715 0.84 MAPK14 (0.71) MAPK14MAPK12HCKTNFCIT
SCHEMBL29594248 0.83 MAPK14 (0.84) MAPK14MAPK12HCKTNFCIT
SCHEMBL295934 0.83 MAPK14 (0.84) MAPK14MAPK12HCKTNFCIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3691620-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2020-08-12 EP disclosed
WO-2019071147-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2019-04-11 WO disclosed
EP-1545514-A1 ANTICOAGULANT AND FIBRINOLYTIC THERAPY USING P38 MAP KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-06-29 EP disclosed
EP-1408950-A2 METHODS OF TREATING CYTOKINE MEDIATED DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-04-21 EP disclosed
WO-2004016267-A1 ANTICOAGULANT AND FIBRINOLYTIC THERAPY USING P38 MAP KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-02-26 WO disclosed
WO-2003005999-A2 METHODS OF TREATING CYTOKINE MEDIATED DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-01-23 WO disclosed